Market Overview

Agios Presents Preclinical Data from Lead Programs at ASH


Agios Pharmaceuticals (NASDAQ: AGIO) today announced that
data from its lead programs were highlighted at the American Society of
Hematology (ASH) Annual Meeting this week in New Orleans.

Two presentations featured in vivo efficacy data in acute
myelogenous leukemia (AML) for the company's lead cancer metabolism
programs targeting IDH1 and IDH2 mutations. In AML and other cancers,
IDH1 and IDH2 mutations initiate and drive cancer growth by blocking
maturation of primitive cells. The data presented at ASH demonstrate
preclinical single agent and combination efficacy of Agios' IDH mutant
inhibitors in patient-derived primary models of AML. Agios also

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (AGIO)

View Comments and Join the Discussion!

Partner Center